metricas

Actas Urológicas Españolas

Sugerencias
Actas Urológicas Españolas La resonancia magnética como herramienta para el diagnóstico del cáncer de pr...
Información de la revista
Vol. 44. Núm. 3.
Páginas 125-206 (Abril 2020)
Cita
Cita
Compartir
Descargar PDF
Más opciones de artículo
Visitas
924
Vol. 44. Núm. 3.
Páginas 125-206 (Abril 2020)
Artículo de revisión

La resonancia magnética como herramienta para el diagnóstico del cáncer de próstata: nuevas evidencias y posicionamiento de la ESUT (EAU Section of Uro-Technology)

Magnetic resonance as imaging diagnostic tool in prostate cancer: New evidences-The EAU Section of Uro-Technology position
Visitas
924
M. Álvarez-Maestroa,b, J. Gómez Rivasa,b, J. Quesada Olartea, D.M. Carrióna, C. Trelles Guzmana, C. Ballesterosa, L.M. Quintanaa, A. Aguilera Bazána,b, L. Martínez-Piñeiroa,b, E. Liatsikosc, E. Barretd
a Departamento de Urología, Hospital Universitario La Paz, Madrid, España
b Instituto de Investigación, Hospital Universitario La Paz (IdiPAZ), Madrid, Spain
c Departamento de Urología, Universidad de Patras, Patras, Grecia
d Departamento de Urologia, Instituto Mutualista Montsouris, Paris, Francia
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Resumen

El cáncer de próstata (CP) es la segunda causa principal de mortalidad por cáncer y la enfermedad diagnosticada con mayor frecuencia en la población masculina. El CP se manifiesta de diversas maneras: desde enfermedad indolente a altamente agresiva. A esto se debe la complejidad de su diagnóstico y de la elección del tratamiento adecuado. El enfoque utilizado actualmente, con pruebas de PSA y examen rectal digital seguido de biopsia transrectal ecodirigida, carece de sensibilidad y especificidad en la detección de CP y ofrece información limitada sobre la agresividad y el estadio del cáncer. La evidencia científica respalda el creciente uso de la resonancia magnética multiparamétrica como la herramienta de imagen más sensible y específica para la detección, la caracterización de lesiones y la estadificación del CP. El presente estudio hace una revisión actualizada del rol de la resonancia magnética en el diagnóstico de CP, revisando los últimos artículos publicados en PubMed.

Palabras clave:
Detección de cáncer de próstata
Resonancia magnética multiparamétrica
Diagnóstico
Biopsia de próstata
Abstract

Prostate cancer (PCa) is the second leading cause of cancer-related mortality and the most frequently diagnosed male malignant disease among men. The manifestation of PCa ranges from indolent to highly aggressive disease and due to this high variation in PCa progression, the diagnosis and subsequent treatment planning can be challenging. The current diagnostic approach with PSA testing and digital rectal examination followed by transrectal ultrasound biopsies lack in both sensitivity and specificity in PCa detection and offers limited information about the aggressiveness and stage of the cancer. Scientific work supports the rapidly growing use of multiparametric magnetic resonance imaging as the most sensitive and specific imaging tool for detection, lesion characterization and staging of PCa. Therefore, we carried out an updated review of magnetic resonance imaging in the diagnostic PCa reviewing the latest papers published in PubMed.

Keywords:
Prostate cancer detection
Multiparametric magnetic resonance imaging
Diagnosis
Prostate biopsy

Artículo

Opciones para acceder a los textos completos de la publicación Actas Urológicas Españolas
Suscriptor
Suscriptor de la revista

Si ya tiene sus datos de acceso, clique aquí.

Si olvidó su clave de acceso puede recuperarla clicando aquí y seleccionando la opción "He olvidado mi contraseña".
Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Comprar ahora
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
M. Boniol, P. Boyle, P. Autier, A. Ruffi, P. Perrin.
Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme.
BJU Int., 110 (2012), pp. 1648-1652
[2]
S. Loeb, M.A. Bjurlin, J. Nicholson, T.L. Tammela, D.F. Penson, H.B. Carter, et al.
Overdiagnosis and overtreatment of prostate cancer.
Eur Urol., 65 (2014), pp. 1046-1055
[3]
Mottet N, van den Bergh RCN, Briers E, Cornford P, de Santis M, Fanti S, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. European Association of Urology Guidelines; 2019.
[4]
S. Hempel, J. Wilby, L. Myers, L.M. Bachmann, J. Kleijnen.
Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: A systematic review.
[5]
M. Smeenge, J. Barentsz, D. Cosgrove, J. de la Rosette, T. de Reijke, S. Eggener, et al.
Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: Report from a consensus panel.
[6]
K.K. Hodge, J.E. McNeal, T.A. Stamey.
Ultrasound guided transrectal core biopsies of the palpably abnormal prostate.
[7]
M.S. Cohen, R.S. Hanley, T. Kurteva, R. Ruthazer, M.L. Silverman, A. Sorcini, et al.
Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: The Lahey Clinic Medical Center experience and an international meta-analysis.
Eur Urol., 54 (2008), pp. 371-381
[8]
J.J. Fütterer, A. Briganti, P. de Visschere, M. Emberton, G. Giannarini, A. Kirkham, et al.
Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature.
Eur Urol, 68 (2015), pp. 1045-1053
[9]
Y. Poon, W. McCallum, M. Henkelman, B. Sutcliffe, A.S. Jewett.
Magnetic resonance imaging of the prostate.
Radiology., 154 (1985), pp. 143-149
[10]
National Institute for Health and Care Excellence. Prostate cancer: Diagnosis and management. NICE guideline [NG131]. NICE; 2019. Disponible en: https://www.nice.org.uk/guidance/ng131/chapter/Recommendations#assessment-and-diagnosis
[11]
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. NCCN; 2019. Disponible en: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
[12]
P.C. Moldovan, T. van den Broeck, R. Sylvester, L. Marconi, J. Bellmunt, R.C.N. van den Bergh, et al.
What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer guidelines panel.
Eur Urol, 72 (2017), pp. 250-266
[13]
H.B. Carter, P.C. Albertsen, M.J. Barry, R. Etzioni, S.J. Freedland, K.L. Greene, et al.
Early detection of prostate cancer: AUA guideline.
J Urol, 190 (2013), pp. 419-426
[14]
A. Stabile, F. Giganti, M. Emberton, C.M. Moore.
MRI in prostate cancer diagnosis: Do we need to add standard sampling? A review of the last 5 years.
Prostate Cancer Prostatic Dis., 21 (2018), pp. 473-487
[15]
F. Bratan, I. Niaf, C. Melodelima, A.E.L. Chesnais, R. Souchon, F. Mège-Lechevallier, et al.
Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: A prospective study.
Eur Radiol, 23 (2013), pp. 2019
[16]
J.J. Futterer, A. Briganti, P. De Visschere, M. Emberton, G. Giannarini, A. Kirkham, et al.
Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature.
[17]
F. Porpiglia, M. Manfredi, F. Mele, M. Cossu, E. Bollito, A. Veltri, et al.
Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: Results from a randomized prospective study in biopsy-naive patients with suspected prostate cancer.
[18]
H.U. Ahmed, A. El-Shater Bosaily, L.C. Brown, R. Gabe, R. Kaplan, M.K. Parmar, et al.
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study.
[19]
G. Kır, H. Seneldir, E. Gumus.
Outcomes of Gleason score 3+4=7 prostate cancer with minimal amounts (<6%) vs≥6% of Gleason pattern 4 tissue in needle biopsy specimens.
Ann Diagn Pathol, 20 (2016), pp. 48-51
[20]
N.J. Sathianathen, D.G. Murphy, R.C. van den Bergh, N. Lawrentschuk.
Gleason pattern 4: Active surveillance no more.
BJU Int, 117 (2016), pp. 856-857
[21]
J.E. Thompson, P.J. van Leeuwen, D. Moses, R. Shnier, P. Brenner, W. Delprado, et al.
The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer.
J Urol, 195 (2016), pp. 1428-1435
[22]
V. Kasivisvanathan, A.S. Rannikko, M. Borghi, V. Panebianco, L.A. Mynderse, M.H. Vaarala, et al.
MRI-targeted or standard biopsy for prostate-cancer diagnosis.
N Engl J Med, 378 (2018), pp. 1767-1777
[23]
E. Baco, E. Rud, L.M. Eri, G. Moen, L. Vlatkovic, A. Svindland, et al.
A randomized controlled trial to assess and compare the outcomes of two-core prostate biopsy guided by fused magnetic resonance and transrectal ultrasound images and traditional 12-core systematic biopsy.
Eur Urol, 69 (2016), pp. 149-156
[24]
P.P. Tonttila, J. Lantto, E. Pääkkö, U. Piippo, S. Kauppila, E. Lammentausta, et al.
Prebiopsy multiparametric magnetic resonance imaging for prostate cancer diagnosis in biopsy naive men with suspected prostate cancer based on elevated prostate-specific antigen values: Results from a randomized prospective blinded controlled trial.
Eur Urol, 69 (2016), pp. 419-425
[25]
M.R. Pokorny, M. de Rooij, E. Duncan, F.H. Schröder, R. Parkinson, J.O. Barentsz, et al.
Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.
[26]
C.P. Filson, S. Natarajan, D.J. Margolis, J. Huang, P. Lieu, F.J. Dorey, et al.
Prostate cancer detection with magnetic resonance ultrasound fusion biopsy: The role of systematic and targeted biopsies.
Cancer, 122 (2016), pp. 884-892
[27]
O. Rouvière, P. Puech, R. Renard-Penna, M. Claudon, C. Roy, F. Mège-Lechevallier, MRI-FIRST Investigators, et al.
Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): A prospective, multicentre, paired diagnostic study.
Lancet Oncol, 20 (2019), pp. 100-109
[28]
M. Van der Leest, E. Cornel, B. Israël, R. Hendriks, A.R. Padhani, M. Hoogenboom, et al.
Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: A large prospective multicenter clinical study.
Eur Urol., 75 (2019), pp. 570-578
[29]
C.M. Moore, V. Kasivisvanathan, S. Eggener, M. Emberton, J.J. Futterer, I.S. Gill, Standards of reporting for MRI targeted biopsy studies (START) of the prostate: Recommendations from an international working group, et al.
Eur Urol, 64 (2013), pp. 544-552
[30]
C.M. Moore, F. Giganti, P. Albertsen, C. Allen, C. Bangma, A. Briganti, et al.
Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: The PRECISE recommendations–A report of a European school of oncology task force.
Eur Urol., 71 (2017), pp. 648-655
[31]
J. Gómez Rivas, F. Giganti, M. Álvarez-Maestro, M.J. Freire, V. Kasivisvanathan, L. Martinez-Piñeiro, et al.
Prostate indeterminate lesions on magnetic resonance imaging-biopsy versus surveillance: A literature review.
Eur Urol Focus, 5 (2019), pp. 799-806
[32]
T. Barrett, A. Rajesh, A.B. Rosenkrantz, P.L. Choyke, B. Turkbey.
PI-RADS version 2.1: One small step for prostate MRI.
Clin Radiol., 74 (2019), pp. 841-852
[33]
I.G. Schoots, D. Nieboer, F. Giganti, C.M. Moore, C.H. Bangma, M.J. Roobol.
Magnetic resonance imaging in active surveillance of prostate cancer: A systematic review.
Eur Urol., 67 (2015), pp. 627-636
[34]
O. Wegelin, L. Exterkate, M. van der Leest, J.A. Kummer, W. Vreuls, P.C. de Bruin, et al.
The FUTURE Trial: A multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies.
Eur Urol., 75 (2019), pp. 582-590
[35]
M. Van der Leest, B. Isräel, E.B. Cornel, P. Zámecnik, I.G. Schoots, H. van del Lelij, et al.
High diagnostic performance of short magnetic resonance imaging protocols for prostate cancer detection in biopsy-naïve men: The next step in magnetic resonance imaging accessibility.
Eur Urol., 76 (2019), pp. 574-581
[36]
Z.K. Shah, S.N. Elias, R. Abaza, D.L. Zynger, L.A. DeRenne, M.V. Knopp, et al.
Performance comparison of 1.5T endorectal coil MRI with non-endorectal coil 3.0T MRI in patients with prostate cancer.
Acad Radiol., 36 (2016), pp. 1011-1014
[37]
T. Ullrich, M. Quentin, C. Oelers, F. Dietzel, L.M. Sawicki, C. Arsov, et al.
Magnetic resonance imaging of the prostate at 1.5 versus 3.0T: A prospective comparison study of image quality.
Eur J Radiol., 90 (2017), pp. 192-197
[38]
J.E. Thompson, D. Moses, R. Shnier, P. Brenner, W. Delprado, L. Ponsky, et al.
Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: A prospective study.
[39]
J.C. Weinreb, J.O. Barentsz, P.L. Choyke, F. Cornud, M.A. Haider, K.J. Macura, et al.
PI-RADS prostate imaging–Reporting and data system: 2015, version 2.
[40]
N.J. Sathianathen, C.A. Warlick.
The use of magnetic resonance imaging in the prostate cancer primary diagnostic pathway: Is it ready for primetime?.
World J Mens Health, 36 (2018), pp. 223-229
[41]
A. Stabile, F. Giganti, A. Rosenkrantz, S. Taneja, G. Villeirs, I.S. Gill, et al.
Multiparametric MRI for prostate cacer diagnosis: Current status and future directions.
[42]
M. De Rooij, S. Crienen, J.A. Witjes, J.O. Barentsz, M.M. Rovers, J.P. Grutters.
Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: A modelling study from a health care perspective.
Eur Urol., 66 (2014), pp. 430-436
[43]
M. De Rooij, E.H. Hamoen, J.A. Witjes, J.O. Barentsz, M.M. Rovers.
Accuracy of magnetic resonance imaging for local staging of prostate cancer: A diagnostic meta-analysis.
asdasdasd
Opciones de artículo
Herramientas